Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Equivalents: 2016-2024

Historic Cash & Equivalents for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $51.9 million.

  • Akebia Therapeutics' Cash & Equivalents rose 389.27% to $166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.4 million, marking a year-over-year increase of 389.27%. This contributed to the annual value of $51.9 million for FY2024, which is 20.84% up from last year.
  • As of FY2024, Akebia Therapeutics' Cash & Equivalents stood at $51.9 million, which was up 20.84% from $42.9 million recorded in FY2023.
  • Akebia Therapeutics' Cash & Equivalents' 5-year high stood at $228.7 million during FY2020, with a 5-year trough of $42.9 million in FY2023.
  • In the last 3 years, Akebia Therapeutics' Cash & Equivalents had a median value of $51.9 million in 2024 and averaged $61.8 million.
  • In the last 5 years, Akebia Therapeutics' Cash & Equivalents spiked by 55.10% in 2020 and then plummeted by 52.55% in 2023.
  • Akebia Therapeutics' Cash & Equivalents (Yearly) stood at $228.7 million in 2020, then tumbled by 34.50% to $149.8 million in 2021, then crashed by 39.61% to $90.5 million in 2022, then plummeted by 52.55% to $42.9 million in 2023, then rose by 20.84% to $51.9 million in 2024.